Abstract
Background: Anaemia is a known risk factor for cardiovascular disease and treating anaemia in chronic kidney disease (CKD) may improve outcomes. However, little is known about the scope to improve primary care management of anaemia in CKD.
Methods: An observational study (N = 1,099,292) with a nationally representative sample using anonymised routine primary care data from 127 Quality Improvement in CKD trial practices (ISRCTN5631023731). We explored variables associated with anaemia in CKD: eGFR, haemoglobin (Hb), mean corpuscular volume (MCV), iron status, cardiovascular comorbidities, and use of therapy which associated with gastrointestinal bleeding, oral iron and deprivation score. We developed a linear regression model to identify variables amenable to improved primary care management.
Results: The prevalence of Stage 3-5 CKD was 6.76%. Hb was lower in CKD (13.2 g/dl) than without (13.7 g/dl). 22.2% of people with CKD had World Health Organization defined anaemia; 8.6% had Hb
Conclusions: Medication review is needed in people with CKD and anaemia prior to considering erythropoietin or parenteral iron. Iron stores may be depleted in over > 60% of people with normocytic anaemia. Prescribing oral iron has not corrected anaemia.
| Original language | English |
|---|---|
| Article number | 24 |
| Number of pages | 9 |
| Journal | BMC Nephrology |
| Volume | 14 |
| DOIs | |
| Publication status | Published - 25 Jan 2013 |
Keywords
- Aspirin
- Chronic
- Anaemia
- Data collection
- Erythropoietin
- Family practice
- Iron-deficiency
- Medical records systems
- Computerized
- Renal insufficiency chronic
- NUTRITION EXAMINATION SURVEY
- ERYTHROPOIESIS-STIMULATING AGENTS
- GLOMERULAR-FILTRATION-RATE
- 3RD NATIONAL-HEALTH
- RECOMBINANT-HUMAN-ERYTHROPOIETIN
- CONGESTIVE-HEART-FAILURE
- EARLY EVALUATION PROGRAM
- COLLECTED COMPUTER-DATA
- VENTRICULAR MASS INDEX
- CARDIOVASCULAR-DISEASE
